PARP inhibition in breast cancer: progress made and future hopes

PARP inhibitors have been approved for the treatment of metastatic breast cancer in germline BRCA mutation (gBRCAm) carriers. The recent OlympiA trial demonstrated improved progression-free and distant disease-free survival with adjuvant olaparib for gBRCAm carriers with HER2-negative high-risk earl...

Descripción completa

Detalles Bibliográficos
Autores principales: Tung, Nadine, Garber, Judy E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993852/
https://www.ncbi.nlm.nih.gov/pubmed/35396508
http://dx.doi.org/10.1038/s41523-022-00411-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993852/
https://www.ncbi.nlm.nih.gov/pubmed/35396508
http://dx.doi.org/10.1038/s41523-022-00411-3

Ejemplares similares